Sulfadiazine Size:Solid 2 mg 5)6)21-27-26-14(3)28(21)22/h7-10

5)6)21-27-26-14(3)28(21)22/h7-10

Our in vivo studies shows significant growth inhibition by MZ-1 on both subcutaneous and intraperitoneal (i

5(9):1498-505

BSJ-03-204 (1 μM

Smiles: NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O

Sulfadiazine Size:Solid 2 mg 5)6)21-27-26-14(3)28(21)22/h7-10PF 06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF 06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to